Post by Chiesi Group

We are pleased to announce that Chiesi Group has entered into an agreement to acquire KalVista Pharmaceuticals, marking the largest acquisition in our history to date. This milestone reinforces our long‑term commitment to advancing innovation for people living with rare conditions, by expanding our Global Rare Diseases portfolio with the first oral, on‑demand treatment for hereditary angioedema. Together, we will combine science, innovation and expertise to address areas of high unmet need and accelerate patient access worldwide. Link to press release: https://lnkd.in/dMu3ut4d Chiesi Global Rare Diseases